NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Remepy

Remepy

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.remepy.com/

Last Round

Seed

May 1, 2024

Total Funding Raised

$15M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Remepy is a biotechnology company that develops hybrid drugs, which combine traditional medications with digital therapeutic software to enhance treatment effectiveness.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Patient Engagement

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

digital therapeuticsDTxhybrid drugssoftware as a medical deviceSaMDmedical AIpatient engagementclinical trialspersonalized medicineneurological therapyprescription digital therapeuticsPDxtreatment adherencehealth tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Remepy Comps

Public and private peers based on sector, stage, and business model.

Remepy comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Remepy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 1, 2024

Key People

Founding team and executive leadership

Amir Amedi

Co-founder And Chief Scientific Officer, Co-Founder

Founding Team

Or Shoval

Co-Founder Co-CEO

Founding Team

Renan Gutman

Chief Product Officer

Executive Team

Remepy Investors

Notable investors and investment history

Remepy investors
InvestorRounds
Vine VenturesSeed
NFXSeed
Fresh.FundPre Seed, Seed
FirstimeSeed
StageNext FundPre Seed, Seed
TechAvivSeed, Pre Seed
Supernode VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2026

    Grew 16% QoQ, from 67 to 78 employees.

  • Apr 28, 2026

    Collaborating with Merck KGaA on hybrid drugs combining pharmaceuticals and digital therapies.

Remepy Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Remepy Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Remepy's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range78
Year Founded2021
Last FundingMay 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.